Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Disease Dementia (PDD) Clinical Trial

Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Disease Dementia (PDD) Clinical Trial   NEW YORK – January 27, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s…

Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrome and Multiple Sclerosis

Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrome and Multiple Sclerosis   NEW YORK – January 8, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease,…

Anavex Life Sciences Reports Fiscal Year 2019 Financial Results  And Provides Clinical Study Updates

  Anavex Life Sciences Reports Fiscal Year 2019 Financial Results  And Provides Clinical Study Updates   Conference Call and Webcast Today at 4:30 p.m. ET   NEW YORK – December 16, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative…

Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019

Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 Conference Call and Webcast To be Held Monday December 16, 2019 4:30pm Eastern Time NEW YORK – December 10, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for…

Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Conference

Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Conference Baseline-matched Real-World external Control Data with Alzheimer’s Disease Neuroimaging Initiative (ADNI): ANAVEX®2-73 (blarcamesine) Cohort showed a Significantly lower Cognitive Decline Compared to the ADNI Control Cohort at Interim 2-Year (104-Week) Timepoint Abundance of Lachnospiraceae and Enterobacteriaceae Families as…

Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome

Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome   NEW YORK – November 14, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease,…

Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome

Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome  Published in Pharmacology Biochemistry and Behavior, Results Highlight Improvements in Multiple Motor, Sensory, and Autonomic Phenotypes Associated with Rett Syndrome Study Provided Proof-of-Concept for Ongoing ANAVEX®2-73 (blarcamesine) Phase 2 Trials NEW YORK – November 6, 2019 – Anavex Life Sciences Corp.…

Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease 

Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease  The ATTENTION-AD extension study will offer the 450 patients enrolled in the on-going Phase 2b/3 ANAVEX®2-73 73 (blarcamesine) Early Alzheimer’s disease study the opportunity to continue their treatment for an additional two years and will provide additional tolerability and efficacy data  …

Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’s Disease

Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’s Disease NEW YORK – October 2, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s…

Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study

Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study NEW YORK – September 27, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and…